Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Sells $657,073.89 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 6,831 shares of the business’s stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $96.19, for a total transaction of $657,073.89. Following the completion of the sale, the chief executive officer owned 169,402 shares of the company’s stock, valued at approximately $16,294,778.38. The trade was a 3.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Christopher Peetz also recently made the following trade(s):

• On Thursday, January 22nd, Christopher Peetz sold 7,098 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $93.33, for a total transaction of $662,456.34.

Mirum Pharmaceuticals Stock Performance

Mirum Pharmaceuticals stock opened at $102.92 on Friday. The firm has a fifty day simple moving average of $79.65 and a two-hundred day simple moving average of $71.96. The company has a quick ratio of 3.16, a current ratio of 3.31 and a debt-to-equity ratio of 1.06. Mirum Pharmaceuticals, Inc. has a twelve month low of $36.88 and a twelve month high of $103.81. The company has a market capitalization of $5.29 billion, a PE ratio of -119.67 and a beta of 0.48.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.15. The firm had revenue of $133.01 million for the quarter, compared to the consensus estimate of $130.11 million. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The company’s quarterly revenue was up 47.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.30) earnings per share. Research analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on MIRM. Evercore ISI restated an “outperform” rating and issued a $101.00 target price on shares of Mirum Pharmaceuticals in a report on Tuesday, January 20th. Raymond James Financial reiterated a “strong-buy” rating and set a $110.00 price target on shares of Mirum Pharmaceuticals in a report on Thursday, December 11th. Robert W. Baird raised their price target on shares of Mirum Pharmaceuticals from $80.00 to $88.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. JMP Securities set a $95.00 price objective on shares of Mirum Pharmaceuticals in a research report on Wednesday, November 5th. Finally, Morgan Stanley increased their target price on shares of Mirum Pharmaceuticals from $81.00 to $95.00 and gave the stock an “overweight” rating in a report on Tuesday, December 9th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $104.92.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. MCF Advisors LLC boosted its stake in shares of Mirum Pharmaceuticals by 76.4% during the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after purchasing an additional 185 shares in the last quarter. Quantbot Technologies LP purchased a new stake in Mirum Pharmaceuticals in the third quarter worth about $33,000. Comerica Bank boosted its position in Mirum Pharmaceuticals by 45.1% during the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after acquiring an additional 278 shares in the last quarter. Quarry LP purchased a new position in shares of Mirum Pharmaceuticals during the 3rd quarter worth approximately $41,000. Finally, CWM LLC raised its position in shares of Mirum Pharmaceuticals by 30.8% in the 3rd quarter. CWM LLC now owns 683 shares of the company’s stock worth $50,000 after acquiring an additional 161 shares in the last quarter.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.